A bioassay of @entity16345 , an amebicide and anticancer drug, for possible carcinogenicity was conducted by administering the test material by intraperitoneal injection to @entity35 and B6C3F1 @entity19 . Groups of 35 @entity35 of each sex were administered @entity16345 at one of two doses, either 0.5 or 1 mg/kg body weight, three times per week for 52 weeks, and then observed for an additional 31 or 32 weeks. Control groups of each sex consisted of 10 untreated @entity35 (untreated controls) and 10 @entity35 injected with buffered saline (vehicle controls). Pooled-control groups, used for statistical evaluation, consisted of the vehicle-control @entity35 of each sex for this study combined with 15 vehicle-control @entity35 of each sex from a similar bioassay of another test chemical. All surviving @entity35 were killed at 83 or 84 weeks. Initially, groups of 35 @entity19 of each sex were administered @entity16345 at one of two doses, either 3.2 or 6.4 mg/kg body weight (mid- and high-dose), three times per week. Control groups of each sex consisted of 15 untreated @entity19 (untreated controls) and 15 @entity19 injected with buffered saline (vehicle controls). Due to high mortality rates in the initial treated groups, additional groups of 35 @entity19 of each sex were later put on study at 1.6 mg/kg (low-dose), together with 10 untreated-control and 10 vehicle-control @entity19 of each sex. The high-dose males were treated for 28 weeks and the mid- and high-dose females for 40 and 33 weeks, respectively. Mid- and low-dose male @entity19 and low-dose female @entity19 were treated for 52 weeks, and then observed for an additional 20 or 26 weeks. All surviving @entity19 were killed at 78-83 weeks. @entity16345 was toxic to male @entity35 at the high dose, to both sexes of @entity19 at the high and mid doses and to a lesser extent at the low dose, as shown by the low survival in these groups. Twenty-six percent of the high-dose male @entity35 and 69% of the high-dose female @entity35 , but none of the high- and mid-dose @entity19 of either sex, survived to the end of the study. In the low-dose @entity19 , 30/35 males and 21/35 females lived at least 1 year, and the median time on study was 72 weeks for males and 59 weeks for females. No @entity5 occurred at a statistically significant incidence in treated @entity35 or @entity19 compared with controls; however, it should be noted that in this study, treatment of both species was stopped at week 52 and the studies were terminated by week 83, which is earlier than in current bioassays where animals are treated until termination of the studies at 2 years. In addition, there was poor survival among the treated @entity19 . It is concluded that the results of this study do not allow evaluation of the possible carcinogenicity of @entity16345 .

Bioassay of XXXX for possible carcinogenicity.

@entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity16345 :: ('MESH:D004640', 'Chemical') :: ['Emetine', 'emetine']
@entity16345 :: (MESH:D004640,Chemical) :: ['emetine']
